Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study - The Journal of Allergy and Clinical Immunology: In Practice
FDA Will Review Teva's BLA for Asthma Drug Reslizumab
Reslizumab Reslizumab (Teva) | Bioz | Ratings For Life-Science Research
CINQAIR® (reslizumab) Injection – About Asthma Control
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials - The Lancet Respiratory Medicine
Upcoming Reslizumab PDUFA- Approval Odds, And What It Means For Teva (NYSE: TEVA) | Seeking Alpha
Reslizumab – All About Drugs
Injectable asthma drug reslizumab approved by European Commission - The Pharmaceutical Journal
Summary of ongoing reslizumab studies in patients with eosinophilic asthma. | Download Table
Chest Medicine Made Easy-Dr Deepu: FDA approves Injectable drug for uncontrolled Asthma
Clinical Outcomes and Health-Care Resource Use Associated With Reslizumab Treatment in Adults With Severe Eosinophilic Asthma in Real-World Practice - CHEST
Rx Item-Cinqair (Reslizumab) 10Mg/Ml Inj Sinle Use Vial 10Ml By Teva Respiratory
Brand name: Auvi-Q
cinqaero - Twitter Search / Twitter
A Guide to the PRESCRIPTION AND SERVICE REQUEST FORM FOR CINQAIR® ( reslizumab) Injection
New Severe Asthma Rx Gets Green Light | RxWiki
Home-based intravenous treatment with reslizumab for severe asthma in the Netherlands – An evaluation - Respiratory Medicine
Teva files MAA for asthma treatment reslizumab
Israeli Pharma gets FDA Approval for Asthma Antibody
Teva announces FDA approval for asthma injection, Cinqair | Pharmafile
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
Teva's Asthma Segment: What Could Boost Its Revenues in 2016?
Dosing and Administration
Teva's severe eosinophilic asthma drug Cinqaero wins EU approval